so true terang, we don't have conclusive proof either way on how the ddRNAi benitec is deploying works.
Based on privately owned Calimmune and Gradalis having expanded their pipelines, not stalled or gone backwards, ddRNAi can't be a total dog.
As for RNAi, talk of Alnylam being a takeover target of Amgen, vindicates Maragnore's stance in the face of criticism from all angles only a few short years back.
Cambridge, Mass.-based Alnylam Pharmaceuticals is currently developing ALN-PCSsc, to cut cholesterol levels. Amgen made an entry into the cardiovascular market with the launch of Repatha, a PCSK-9 inhibitor. In July, Repatha (evolocumab) was approved for use in Europe, and in August approved for use in the U.S.
Aliya Kaleem, writing for BidnessEtc., says, “To strengthen its position in the cardiovascular therapeutic area, Alnylam Pharmaceuticals could be Amgen’s best bet. The $5 billion drug maker is developing a cholesterol-lowering treatment, called ALN-PCSsc, which reduces bad cholesterol levels in patients by more than 50 percent. Moreover, the treatment proved to be effective for a relatively long period of six months.”
Alnylam hopes to launch the drug in 2017. Scooping it up would expand Amgen’s foothold in this market while eliminating a potential competitor.
BLT Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
